COVID-19 vaccine effectiveness and variants in Nepal: study protocol for a test-negative case–control study with SARS-CoV-2 genetic sequencing

Author:

Bijukchhe Sanjeev MORCID,O'Reilly Peter J,Theiss-Nyland Katherine,Gurung Meeru,Pokhrel Bhishma,Kelly Sarah,Acharya Samita,Maharjan Shreekrishna,Shrestha Ashis,Pandey Bimal,Lama Mipsang,Shrestha Ira,Voysey Merryn,Eordogh Agnes,Shrestha Sonu,Feng Elaine Shuo,Li Grace,Shah Ganesh,Pollard Andrew JORCID,Shrestha Shrijana

Abstract

IntroductionInactivated, viral vector and mRNA vaccines have been used in the Nepali COVID-19 vaccination programme but there is little evidence on the effectiveness of these vaccines in this setting. The aim of this study is to describe COVID-19 vaccine effectiveness in Nepal and provide information on infections with SARS-CoV-2 variants.Methods and analysisThis is a hospital-based, prospective test-negative case–control study conducted at Patan Hospital, Kathmandu. All patients >18 years of age presenting to Patan Hospital with COVID-19-like symptoms who have received a COVID-19 antigen/PCR test are eligible for inclusion. The primary outcome is vaccine effectiveness of licensed COVID-19 vaccines against laboratory-confirmed COVID-19 disease.After enrolment, information will be collected on vaccine status, date of vaccination, type of vaccine, demographics and other medical comorbidities. The primary outcome of interest is laboratory-confirmed SARS-CoV-2 infection. Cases (positive for SARS-CoV-2) and controls (negative for SARS-CoV-2) will be enrolled in a 1:4 ratio. Vaccine effectiveness against COVID-19 disease will be analysed by comparing vaccination status with SARS-CoV-2 test results.Positive SARS-CoV-2 samples will be sequenced to identify circulating variants and estimate vaccine effectiveness against common variants.Measuring vaccine effectiveness and identifying SARS-CoV-2 variants in Nepal will help to inform public health efforts. Describing disease severity in relation to specific SARS-CoV-2 variants and vaccine status will also inform future prevention and care efforts.Ethics and disseminationEthical approval was obtained from the University of Oxford Tropical Ethics Committee (OxTREC) (ref: 561-21) and the Patan Academy of Health Sciences Institutional Review Board (ref: drs2111121578). The protocol and supporting study documents were approved for use by the Nepal Health Research Council (NHRC 550-2021). Results will be disseminated in peer-reviewed journals and to the public health authorities in Nepal.

Funder

AstraZeneca

Publisher

BMJ

Subject

General Medicine

Reference16 articles.

1. The first 2019 novel coronavirus case in Nepal

2. Shrestha R , Shrestha S , Khanal P , et al . Nepal’s first case of COVID-19 and public health response. J Travel Med 2020;27:taaa024. doi:10.1093/jtm/taaa024

3. Worldometer . Wordometer - nepal coronavirus update. 2021. Available: https://www.worldometers.info/coronavirus/country/nepal/ [Accessed 19 May 2021].

4. India To . Nepal confirms presence of third and new variant of coronavirus. 2021. Available: https://timesofindia.indiatimes.com/world/south-asia/nepal-confirms-presence-of-third-and-new-variant-of-coronavirus/articleshow/82761558.cms [Accessed 19 May 2021].

5. COVID-19 vaccine development to vaccination;Pandey;J Nepal Health Res Counc,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3